🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
726 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer
2025-525040-18-00triple‑negative breast cancer
Institut Paoli Calmettes
Neoplasms
France
24/07/2026
Phase II
functional imaging of digital osteoarthritis and rheumatoid arthritis using 99mTc-NTP15-5 in nuclear medicine : phase II clinical study
2025-523650-14-00Arthritis rheumatoid and finger osteoarthritis
Centre Jean Perrin
Not possible to specify
France
24/07/2026
Phase II
A randomised active-controlled trial to assess the safety and pharmacodynamics of two blinded doses of vortosiran and open-label apixaban in patients with non-valvular atrial fibrillation
2026-525417-31-00non-valvular atrial fibrillation
Ribocure Pharmaceuticals AB
Cardiovascular Diseases
Norway, Denmark, Poland, Sweden
24/07/2026
Phase II
Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors
2025-524125-40-01Metastatic solid tumors, with the following specific indica…
Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets
Neoplasms
Italy
23/07/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)
2025-524918-28-00VEXAS Syndrome
Sironax USA Inc.
Immune System Diseases
Italy
23/07/2026
Phase II
IKF-099/D-FLOT-TNT Total Neoadjuvant Treatment with preoperative FLOT/Durvalumab plus postoperative Durvalumab for Resectable Gastroesophageal Adenocarcinoma
2026-525185-21-00Gastroesophageal Adenocarcinoma
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Digestive System Diseases
Germany, Spain
23/07/2026
Phase II
Local and systemic immune modulation by Rilvegostomig (AZD2936) in the treatment of advanced gastric cancer (RILVE Project)
2026-525620-23-00advanced gastric cancer
Vall D Hebron Institute Of Oncology
Digestive System Diseases
Spain
22/07/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
2025-523390-42-00Early-Stage Down Syndrome-Associated Alzheimer’s Disease (D…
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
Italy, Netherlands, Spain, Germany, Ireland
22/07/2026
Phase II
Randomized Controlled Trial Assessing the Effectiveness and Safety of Fecal Microbiota Transfer for VRE Eradication in Immunocompromised Patients (EU CTR, Phase II) – VRE-ex
2026-525632-41-00Intestinal colonization with vancomycin-resistant enterococ…
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
Bacterial Infections and Mycoses
Germany
21/07/2026
Phase II
A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)
2025-522803-60-00newly diagnosed amyloid light chain amyloidosis
Glaxosmithkline Research & Development Limited
Immune System Diseases
Italy, Greece, Spain
21/07/2026
Phase II
J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
2025-523258-15-00Breast Neoplasms
Eli Lilly & Co.
Neoplasms
Belgium, France, Italy, Germany
21/07/2026
Phase II
DOXYCYCLINE PENETRATION INTO BONE AND JOINT.
2025-524744-36-00Patients requiring total hip arthroplasty for coxofemoral o…
Centre Hospitalier Universitaire De Caen Normandie
Bacterial Infections and Mycoses
France
20/07/2026
Phase II
Randomized Phase II study of multi-peptide vaccination and bispecific PSMAxCD3 antibody treatment in patients with biochemical relapse of prostate cancer
2025-522144-41-00biochemical relapse of prostate cancer
Universitaetsklinikum Tuebingen AöR
Male Urogenital Diseases
Germany
20/07/2026
Phase II
HOVON 180 CLL: Prospective phase II trial of pirtobrutinib treatment (24 cycles) with 12 cycles of epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. ODYSSEUS study (Outcome-Driven trial for relapsed CLL/SLL combining BTK and bispecific antibodY to improve outcome)
2025-524842-89-00chronic lymphocytic leukemia (CLL) and small lymphocytic ly…
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Netherlands
20/07/2026
Phase II
A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY
2026-525736-42-00Multiple Myeloma (MM)
F. Hoffmann-La Roche AG
Neoplasms
Germany
20/07/2026
Phase II
A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
2025-523908-75-00Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca AB
Cardiovascular Diseases
Germany, Italy, Spain, France, Sweden
20/07/2026
Phase II
A Phase 2a, multi centric, open label clinical study to explore the safety and tolerability, the pharmacokinetics and pharmacodynamics profile and first signs of efficacy of PTI5803 administered as adjunctive therapy with a 3-dose escalation regimen in patients >= 14 years of age with drug-resistant seizures associated to focal cortical dysplasia, followed by an optional open-label extension study.
2026-525162-21-00Drug resistant seizures associated to Focal Cortical Dyspla…
PannTheraPi
Nervous System Diseases
France
20/07/2026
Phase II
An open label multicenter phase II study to investigate the efficacy, safety and tolerability of the Obe-cel in patients with minimal residual disease (MRD) of Philadelphia negative (Ph neg) B-precursor acute lymphoblastic leukaemia (B-ALL) - GMALL-OBECEL
2025-524169-26-00Ph-negative CD19 positive B-precursor ALL patients in CR1 w…
Goethe University Frankfurt
Hemic and Lymphatic Diseases
Germany
20/07/2026
Phase II
SETRAPED : A prospective, multicenter study evaluating the efficacy and tolerance of transmucosal midazolam for proportionate palliative sedation in children with refractory symptoms
2025-523840-11-00Children with refractory symptoms
Centre Leon Berard
Pathological Conditions, Signs and Symptoms
France
17/07/2026
Phase II
An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension due to Interstitial Lung Disease
2026-525810-80-00Pulmonary hypertension secondary to interstitial lung disea…
Tectonic Operating Company Inc.
Cardiovascular Diseases
Poland, Romania, Spain
17/07/2026
Phase II
Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).
2025-523617-29-01Oral cavity squamous cell carcinoma
Amsterdam UMC Stichting
Otorhinolaryngologic Diseases
Netherlands
17/07/2026
Phase II
PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy
2025-523482-23-00neoplastic pleural effusion
Hospices Civils De Lyon
Neoplasms
France
16/07/2026
Phase II
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid
2025-524682-24-00Ulcerative Colitis
Microbial Resource Management Health
Digestive System Diseases
Czechia, Poland, Italy
16/07/2026
Phase II
Randomized, observer-blind, placebo-controlled, four Parallel Group, Clinical Trial for exploring the Efficacy and Tolerability of two different strengths ketotifen nasal spray (Ketotifen 0.025 mcg/ml and 0.050 mcg/ml) vs sodium cromoglicate nasal spray 2% in Patients with Rhinitis
2026-525419-16-00Rhinitis
Eudemus Pharmaceuticals Limited
Otorhinolaryngologic Diseases
Greece
16/07/2026
Phase II
Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)
2024-519985-35-00systemic lupus erythematosus pure membranous nephropathy
Assistance Publique Hopitaux De Paris
Pathological Conditions, Signs and Symptoms
France
15/07/2026
Rows per page Showing 101–125 of 726
Previous 3 4 5 6 7 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.